The purpose of this study is to examine the role of wrist-worn activity monitors (Fitbit) in the care of patients with advanced cancer. The study aims to determine whether changes in participants’ activity, as measured using the Fitbit, are related to changes in their clinical outcomes over the course of the study. Specifically, researchers would like to determine whether an increase or decrease in daily step counts is associated with an improvement or worsening of performance status, as rated by the patient’s oncologist. Researchers will also examine relationships between average weekly Fitbit activity and self-reported symptoms including pain, fatigue, physical functioning, emotional well-being, and sleep quality.

The Fitbit Charge HR is a commercially available biosensor (a device that tracks steps, movement or other activities), but this device has not been approved by the U.S. Food and Drug Administration (FDA) for medical use.